Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
10/2003
10/14/2003US6632427 Adenoviral-vector-mediated gene transfer into medullary motor neurons
10/14/2003US6632424 Stimulate proliferation of hematopoietic stem or progenitor cells
10/14/2003CA2288376C Syndecan interacting proteins and the use thereof
10/12/2003CA2425021A1 Control of the ratio of lap to lip
10/09/2003WO2003083485A2 Protein for use in hypoxia related conditions
10/09/2003WO2003083442A2 Life sciences business systems and methods
10/09/2003WO2003083135A2 Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 2 (npff2)
10/09/2003WO2003083122A1 Treatment and prevention of angiostenosis
10/09/2003WO2003083117A2 Vascularization controlling gene
10/09/2003WO2003083113A2 Growth regulating proteins
10/09/2003WO2003083105A1 Treatment and prevention of angiostenosis
10/09/2003WO2003083089A2 Tolerogenic antigen-presenting cells
10/09/2003WO2003083080A2 Mixed- cell gene therapy
10/09/2003WO2003083079A2 Bone generation by gene therapy
10/09/2003WO2003083057A2 Adipocytes and uses thereof
10/09/2003WO2003083052A2 Method of using anti-apoptotic factors in gene expression
10/09/2003WO2003083050A2 Human deubiquitinating protease gene on chromosome 7 and its murine ortholog
10/09/2003WO2003083039A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/09/2003WO2003083037A2 Minimizing metal toxicity during electroporation enhanced delivery of polynucleotides
10/09/2003WO2003082915A2 Xcrf polynucleotides and polypeptides and uses thereof
10/09/2003WO2003082809A1 Diaminoacid-aminoacid-polyamine based gemini surfactant compounds
10/09/2003WO2003082349A1 Treatment methods for eotaxin mediated inflammatory conditions
10/09/2003WO2003082348A1 Nanogel networks including polyion polymer fragments and biological agent compositions thereof
10/09/2003WO2003082345A1 Drugs comprising protein forming hollow nanoparticles and therapeutic substance to be transferred into cells fused therewith
10/09/2003WO2003082344A1 Remedies with the use of hollow protein nanoparticles presenting growth factor or the like
10/09/2003WO2003082343A1 Drugs for treating liver diseases with the use of hollow protein nanoparticles
10/09/2003WO2003082331A1 Decoy compositions for treating and preventing brain diseases and disorders
10/09/2003WO2003082330A1 Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles
10/09/2003WO2003082323A1 A composition and method for killing of tumours
10/09/2003WO2003082314A2 Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
10/09/2003WO2003082302A2 Bioadhesive directed somatic cell therapy
10/09/2003WO2003082255A2 Use of mob-5 in pain
10/09/2003WO2003082212A2 Method for treating cancer in humans
10/09/2003WO2003082200A2 Potent oncolytic herpes simplex virus for cancer therapy
10/09/2003WO2003082195A2 Protamine-adenoviral vector complexes and methods of use
10/09/2003WO2003082006A2 Methods and compositions for preventing obesity and obesity related disorders
10/09/2003WO2003059376A8 The use of il6r/il6 chimera in nerve cell regeneration
10/09/2003WO2003040686A3 Dosing and administration of therapeutic micro-organs in living subjects and devices and methods for same
10/09/2003WO2003040170A3 Antibodies to cd40
10/09/2003WO2003035048A3 Methods for the treatment of osteoarthritis and compositions thereof
10/09/2003WO2003030725A3 Pancreatic cancer diagnosis and therapies
10/09/2003WO2003022880A3 Synthetic hcv envelope proteins and their use for vaccination
10/09/2003WO2003007889A3 Therapeutic agents comprising pro-apoptotic proteins
10/09/2003WO2003006893A3 Methods of inhibiting amyloid toxicity
10/09/2003WO2002102828A3 Chimeric flavivirus vectors
10/09/2003WO2002069947A3 Antisense oligonucleotides and trichostatin analogue histone deacetylase-4 inhibitors against cancer
10/09/2003WO2002066629A3 Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates
10/09/2003WO2002057429A3 A method for producing a population of homozygous stem cells having a pre-selected immunophenotype and/or genotype
10/09/2003WO2002053743A3 Mammalian tribbles signaling pathways and methods and reagents related thereto
10/09/2003WO2002043769A3 Neutral and anionic colloidal particles for gene delivery
10/09/2003WO2002038797A3 Modulators of bruton's tyrosine kinase, their identification and use
10/09/2003WO2002029072A3 Targetting molecules for adenoviral vectors
10/09/2003WO2002022664A3 Antigenic proteins of shrimp white spot syndrome virus and uses thereof
10/09/2003WO2002020563A3 RECEPTOR IN THE EDb FIBRONECTIN DOMAIN
10/09/2003WO2002016612A3 Genes and proteins, and their uses
10/09/2003WO2002012290A3 Sid polypeptides binding to pathogenic strain of the hepatitis c virus
10/09/2003WO2001085917A3 A device
10/09/2003US20030192066 DNA molecule containing an adenoviral inverted terminal repeat (ITR), a packaging signal, a transcriptional control region, effector or reporter gene, generating an infectious, replication-defective genetic engineered adenoviral vector
10/09/2003US20030191500 System and method for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment
10/09/2003US20030191300 Antisense modulation of bcl-x expression
10/09/2003US20030191084 High affinity nucleic acid ligands of complement system proteins
10/09/2003US20030191082 Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
10/09/2003US20030191081 Polynucleotides; gene therapy; vaccines; efficient gene expression; administering to muscles
10/09/2003US20030191080 Cardiovascular disorders; hypotensive agents
10/09/2003US20030191079 Methods for treating and preventing infectious disease
10/09/2003US20030191077 Method and reagent for the treatment of asthma and allergic conditions
10/09/2003US20030191075 Modulation of gene expression of nucleic acids; sterol binding to oligonucleotides
10/09/2003US20030191074 Antibody therapy; immobilization
10/09/2003US20030191072 Gene therapy for proliferative vitreoretinopathy
10/09/2003US20030191062 Bone marrow specific protein
10/09/2003US20030191054 Novel bag proteins and nucleic acid molecules encoding them
10/09/2003US20030190746 Gene expression control system and its use in recombinant virus packaging cell lines
10/09/2003US20030190715 Novel proteins and nucleic acids encoding same
10/09/2003US20030190709 Modulation apoptosis; Alzheimer's diseases; Parkinson's disease; amyotropic lateral sclerosis
10/09/2003US20030190708 Novel hepatoma-derived growth factor-like proteins, polynucleotides encoding them and methods of use
10/09/2003US20030190707 17 human secreted proteins
10/09/2003US20030190659 Oligomers that hybridize to Inhibition of Apoptosis (IAP) polynucleotides and methods for using them to enhance apoptosis and treat proliferative diseases
10/09/2003US20030190651 Preventing, ameliorating, correcting dysfunctions or diseases such as cancer, peripheral and central nervous system diseases, and chronic obstructive pulmonary disease
10/09/2003US20030190642 Thymus expressed human cytochrome p450(p450tec)
10/09/2003US20030190639 Diagnosis of Cryptogenetic inflammatory bowel diseases (IBDs)
10/09/2003US20030190635 RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
10/09/2003US20030190629 Antisense modulation of PTTG1 expression
10/09/2003US20030190606 Hepatitis C virus NS5B truncated protein and methods thereof to identify antiviral compounds
10/09/2003US20030190348 Cationic amphiphiles for intracellular delivery of therapeutic molecules and its composition, process and method of treatment
10/09/2003US20030190285 Having nucleotide sequence of any one of the strands of any one of the members of the High Mobility Group protein genes or LIM protein genes, including modified versions and derivatives thereof; diagnostic and therapeutic applications
10/09/2003CA2519642A1 A composition and method for killing of tumours
10/09/2003CA2481304A1 Method for treating cancer in humans
10/09/2003CA2480751A1 Tolerogenic antigen-presenting cells
10/09/2003CA2480656A1 Bioadhesive directed somatic cell therapy
10/09/2003CA2480554A1 Bone generation by gene therapy
10/09/2003CA2480263A1 Activation of tumor-reactive lymphocytes via antibodies or genes recognizing cd3 or 4-1bb
10/09/2003CA2479763A1 Potent oncolytic herpes simplex virus for cancer therapy
10/09/2003CA2479759A1 Protamine-adenoviral vector complexes and methods of use
10/09/2003CA2479647A1 Human deubiquitinating protease gene on chromosome 7 and its murine ortholog
10/09/2003CA2479028A1 Minimizing metal toxicity during electroporation enhanced delivery of polynucleotides
10/09/2003CA2448540A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/08/2003EP1350854A1 Catalytic nucleic acid and its medical use
10/08/2003EP1350848A2 T-cell membrane protein (TIRC7), gene encoding it and antibodies against it and uses thereof
10/08/2003EP1350799A2 Inhibitory Immunoglobulin Polypeptides to Human PDGF Beta Receptor
10/08/2003EP1350514A2 Therapeutic use of cis-element decoys in vivo
1 ... 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 ... 870